MedTrace Logo

Cardiac Neuromodulation for Heart Failure

NCT04573699 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 11

Last updated 2022-07-18

No results posted yet for this study

Summary

This investigation will evaluate the ability of the Moderato® System to safely and effectively deliver CNT, to reduce sympathetic activity in heart failure patients

Conditions

  • Heart Failure NYHA Class II
  • Heart Failure NYHA Class III

Interventions

DEVICE

CNT-HF

A modified CNT, will be delivered as a pacing sequence able to acutely influence sympathetic tone.

Sponsors & Collaborators

  • CD Leycom

    collaborator UNKNOWN

  • BackBeat Medical Inc

    lead INDUSTRY

Principal Investigators

  • Zbigniew Kalarus, Prof. MD Ph.D · Silesian Center for Heart Diseases

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-12-15
Primary Completion
2023-01-31
Completion
2023-05-30

Countries

  • Poland

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04573699 on ClinicalTrials.gov